Submit supplemental new drug application for TIBSOVO
Replaced by a different commitment
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 11 Jan 2021
- Due
- 31 Mar 2021
- Replaced
- 31 Mar 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Submit supplemental new drug application (sNDA) in the U.S. for TIBSOVO® in patients with previously treated IDH1-mutant cholangiocarcinoma in the first quarter of 2021”
What we found
Evidence strength A What the grades mean
The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Mar 2021.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +1371 days
- 2 versions
-
Version 1 · original · stated 11 Jan 2021
Deadline 31 Mar 2021 (“in the first quarter of 2021”)
-
Version 2 · stated 8 Jan 2024
Deadline 31 Dec 2024 (“year-end”)
“submit a New Drug Application (NDA) for mitapivat in thalassemia (year-end)”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory submission
- Indicative materiality
- High rules
- Action
- Submit
- Deliverable
- sNDA for TIBSOVO
- Where
- U.S.
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesClaude (Anthropic) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Agios Pharmaceuticals, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-AGIO-021575 · Corrections policy